Press release - April 28, 2008
ImpediMed New Clinical Data & American Society of Breast Surgeons Conference
ImpediMed is pleased to announce the company will be exhibiting at the American Society of Breast Surgeons 9th Annual Meeting, which will take place April 20-May 4 in New York City (USA). The meeting will focus on the latest issues affecting surgeons who treat breast cancer, and it will be an opportunity for the company to network with breast surgeons and discuss how they may preemptively manage breast cancer patients for lymphedema. ImpediMed has the only device FDA cleared for the clinical assessment of lymphedema in the arm. The FDA cleared L-Dex XCA is a device that longer term will be targeted to the home care market. The recently filed L-Dex U400 is the device that once FDA cleared will be targeted to surgeons, and the company hopes to launch this device by the fourth quarter of this year. ImpediMed’s technology has been shown in clinical trials to detect lymphoedema in breast cancer survivors in the range of 1 to 10 months earlier than clinically observable symptoms. The company will also discuss new data following the recent online publication of a study in the journal Cancer entitled “Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. For more information contact: Mel Bridges ImpediMed Limited Chairman Office: +61-7-3423-1777 Greg Brown ImpediMed Limited CEO Office: +61-7-3423-1777 John Lamont Phillips Group Media Relations Mobile: +61-408-737-450 About ImpediMed Limited: ImpediMed Limited develops and globally markets medical device systems for use in non-invasive screening and monitoring of human disorders and diseases. ImpediMed’s primary product range consists of a number of medical devices that enable the early detection and monitoring of secondary lymphoedema in cancer survivors before the onset of symptoms that are detectable using the most commonly used clinical technique. ImpediMed has the only medical device with an FDA clearance in the United States for the clinical assessment by Health Care Providers of secondary lymphoedema in the arm.